“…11 These also correspond to the fourth most frequent fracture during the osteoporosis period, responsible for 12% of all fractures. 12,13 According to Maravic et al 14 , in France, each humerus fracture of osteoporotic origin, generates individual annual costs around US$4,000. Zoledronate, which acts by inhibiting the osteoclastic action and, consequently, decreasing bone resorption, 15 can be used in the prophylaxis of fractures caused by osteoporosis.…”